112 results about "EPA - Eicosapentaenoic acid" patented technology

The invention relates to the technical field of feed products, in particular to a fatty acid composition and application thereof in preparation of products for improving intestinal health. The fatty acid composition comprises arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, butyric acid and lauric acid, or a precursor substance capable of releasing the fatty acid in the digestive tract, and the mass of the fatty acid composition is calculated according to the mass of the arachidonic acid, the mass of the docosahexaenoic acid, the mass of the eicosapentaenoic acid, the mass of the butyric acid and the mass of the lauric acid. The additive is prepared from the following components in parts by weight: 7-10 parts of arachidonic acid, 3-7 parts of docosahexaenoic acid, 3-7 parts of eicosapentaenoic acid, 2-5 parts of butyric acid and 1-3 parts of lauric acid. The composition can effectively relieve inflammation and diarrhea, regulate intestinal flora and improve intestinal health, and drug resistance is not prone to being generated.

The invention provides schizochytrium limacinum FJ-1 and application thereof in production of phospholipid type EPA (eicosapentaenoic acid). The application comprises the following steps: taking a cryopreserved schizochytrium limacinum strain, and inoculating the schizochytrium limacinum strain into a liquid seed culture medium for pre-culture; the method comprises the following steps: inoculating pre-cultured schizochytrium limacinum into a fermentation tank according to the inoculum size of 5-10% v / v, culturing for 48-60 hours at the sea salt concentration of 0.5-1% w / v, fermenting for 48-72 hours, supplementing sea salt to a culture medium in batches until the sea salt concentration is 3-5% w / v, and continuously culturing for 96-120 hours by controlling the glucose concentration and the yeast extract concentration through supplementing materials. The technical problem that the synthesis efficiency of schizochytrium limacinum phospholipid type EPA is low is solved through precise regulation and control of salinity stress, an efficient, economical and generalizable innovative scheme is provided for industrial production of functional lipid, and the method is suitable for large-scale production.

The invention belongs to the technical field of biology, and discloses a yarrowia lipolytica engineering strain for efficiently producing eicosapentaenoic acid based on citric acid metabolism regulation, a method and application of the yarrowia lipolytica engineering strain. Delta9 elongase, Delta8 desaturase, Delta5 desaturase and Delta17 desaturase genes in a fatty acid synthesis route, heterologous ATP-citrate lyase and a mitochondrial citric acid vector are overexpressed. According to the invention, ATP-citric acid lyase and a mitochondrial citric acid carrier gene which are respectively derived from Schizochylene sp. And Saccharomyces cerevisiae are jointly expressed in the yarrowia lipolytica engineering strain, so that the yields of EPA and grease in the yarrowia lipolytica engineering strain are remarkably improved, and compared with a control strain, the yields of the grease and the EPA are respectively improved by 243.35% and 161.85%.

The invention belongs to the technical field of biology, and discloses an exogenous cofactor enhanced yarrowia lipolytica strain, a method and application in efficient synthesis of EPA (eicosapentaenoic acid) and lipids.The chassis strain of the yarrowia lipolytica strain is yarrowia lipolytica Po1f, desaturase is partially prolonged in an overexpression fatty acid synthesis route in the strain, and the EPA and the lipids.The yield of the EPA and the lipids.The yield of the EPA and the lipids.The yield of the EPA and the lipids. The desaturase gene mainly comprises a delta 9 elongase gene, a delta 8 desaturase gene, a delta 5 desaturase gene and a delta 17 desaturase gene, and G6PDH and malic enzyme are overexpressed at the same time on the basis. The strain provided by the invention improves the EPA and lipid yield of yarrowia lipolytica; the method is suitable for constructing a genetic engineering strain with high yield of EPA and lipid, provides a basis for producing grease rich in EPA from yarrowia lipolytica, and solves the problems of non-sustainability, high cost and the like caused by obtaining EPA from fish.

The invention provides a method for separating EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) through supercritical fluid chromatography, and relates to the technical field of separation and purification. The invention provides a method for separating EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) by supercritical fluid chromatography, which comprises the following steps: by taking supercritical carbon dioxide and an organic reagent as mobile phases, and by utilizing the specific mobile phase property of supercritical CO2 after being mixed with the organic reagent (saturated aliphatic hydrocarbon) and matching with a normal-phase chromatographic column, separating the EPA from the DHA by supercritical fluid chromatography. A specific stationary phase (one or more of a silica gel surface bonded propylurea stationary phase, a silica gel surface bonded phenyl stationary phase and a silica gel surface bonded imidazolyl stationary phase) is adopted, effective separation and preparation of the EPA and the DHA in the fish oil can be achieved, the EPA and the DHA in the fish oil can be effectively separated within 50 min, the separation speed is high, the separation effect is good, and the method is suitable for industrial production. The purity of the obtained EPA and DHA is 98% or above, the purity of the EPA and the DHA is high, and the EPA and the DHA have good application prospects in the fields of medicine production and food and health care products.

Preparations may include at least one extract of gum resins from Boswellia species and at least one omega-3 fatty acid salt selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Surprisingly, such combinations of extracts of gum resins from Boswellia species and polyunsaturated fatty acid salt can cause a marked and unexpected increase in the biosynthesis of specialized pro-resolving mediators (SPM) in a synergistic manner, proposing benefit for resolution of inflammatory conditions.

The invention relates to the technical field of feed and fermentation, in particular to compound feed for promoting healthy growth of micropterus salmoides as well as a preparation method and application of the compound feed. The compound feed is prepared from the following components in parts by weight: 30 to 40 parts of fish meal, 10 to 15 parts of chicken meal, 0 to 10 parts of tenebrio molitor protein, 9 to 11 parts of fermented soybean meal, 7.5 to 9.5 parts of egg powder, 1 to 6 parts of beer yeast powder, 4 to 10 parts of flour, 2 to 3.5 parts of cassava starch, 1 to 3 parts of fish oil, 0.6 part of monocalcium phosphate, 0.3 to 1 part of compound vitamin, 1.2 to 3.7 parts of mineral substance mixture, 2 to 3 parts of EPA (eicosapentaenoic acid) and 3 to 4.4 parts of DHA (docosahexaenoic acid). According to the compound feed disclosed by the invention, the fermented soybean meal and the tenebrio molitor protein are combined to replace part of fish meal, so that the cost of the feed is effectively reduced, the organism immunity and disease resistance of the micropterus salmoides are improved, the intestinal health of the micropterus salmoides is improved, and the culture benefit is comprehensively improved.

The invention belongs to the technical field of skin care products, and discloses a quick-acting red-removing repair product which comprises the following components: water, caprylic / capric triglyceride, glycerol, sorbitol, phosphatidylcholine, 1, 3-propylene glycol, xanthan gum, eicosapentaenoic acid, docosahexaenoic acid, phytosphingosine, centella asiatica extract and tocopheryl acetate. A turmeric rhizome extract and 1, 2-hexanediol. Through mutual cooperation of the turmeric root extract and the centella asiatica extract, by taking enhancement of skin immune regulation and skin barrier functions as an action mechanism, on one hand, skin inflammatory response can be inhibited, and inflammation, microorganisms and bacteria can be effectively resisted, and on the other hand, skin barrier reconstruction can be promoted, wound healing can be promoted, and an ECM matrix can be protected; in addition, the eicosapentaenoic acid, the docosahexaenoic acid, the turmeric root extract, the phytosphingosine and the centella asiatica extract are wrapped by the nano-microcapsule liposome, so that the activity of the product can be ensured.

The invention belongs to the technical field of bioengineering, and particularly relates to kluyveromyces marxianus engineering bacteria for synthesizing eicosapentaenoic acid and application of the kluyveromyces marxianus engineering bacteria. According to the engineering bacterium, pyruvate decarboxylase PDC1 genes, alcohol dehydrogenase ADH1 genes and alcohol dehydrogenase ADH2 genes are sequentially knocked out from a kluyveromyces marxianus FIM1 delta ura3 strain; meanwhile, a citrate lyase ACL gene, a pyruvate oxidase PO gene and a phosphate transacetylase PTA gene are inserted into the loci respectively, so that synthesis of acetyl coenzyme A is enhanced; then a plurality of genes are sequentially inserted into a Kluyveromyces marxianus genome, and then a vector of a delta 8 desaturase delta 8D gene is transferred into the Kluyveromyces marxianus genome. The invention also provides a method for efficiently preparing the EPA, namely the Kluyveromyces marxianus engineering strain is used as a fermentation strain, glucose, a yeast extract, peptone and other components are used as a culture medium, and the yield of the EPA produced by culturing and fermenting reaches 8.71 mg / g of dry cell weight.

The invention belongs to the technical field of microbial engineering, and discloses a method for producing eicosapentaenoic acid (EPA) with high yield by schizochytrium limacinum based on random mutation and low-temperature screening and application, and the method comprises the following steps: driving overexpression of a G418 resistance gene through a P2520 promoter, constructing a random insertion mutant library, and screening to obtain a schizochytrium limacinum mutant strain with a randomly mutated genome; coating in a culture medium containing G418 resistance for culturing, and screening out strains which are resistant to low temperature and good in growth state at 15 DEG C; and inoculating into a fermentation culture medium, adding MgSO4 with the final mass concentration of 0.1% at the initial stage of fermentation, supplementing MnCl2 with the final mass concentration of 0.05% when fermentation is performed for 72 hours, and culturing to obtain a mutant strain. According to the invention, the G418 resistance gene carried by the plasmid is randomly inserted into the schizochytrium limacinum genome, and low-temperature induced screening is combined, so that the target limitation of traditional homologous recombination is broken through, and a stable strain with multiple mutation superposition can be obtained through enrichment.

The present invention provides an EPA derivative, a preparation method thereof and uses thereof. The EPA derivative is eicosapentaenoic acid-4-benzyloxybenzyl ester. The present invention belongs to the technical field of medicine and provides an EPA derivative with a novel structure. The EPA derivative is eicosapentaenoic acid-4-benzyloxybenzyl ester (abbreviated as EPA-BE), which is prepared by a one-step synthesis from 4-benzyloxybenzyl alcohol and eicosapentaenoic acid under conditions such as immobilized lipase. This derivative improves the bioavailability of EPA and enhances the therapeutic effect on atherosclerotic cardiovascular diseases.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.

This description describes a method for treating pain by administering a pharmaceutical composition containing a therapeutically effective amount of margaric acid to a subject requiring pain treatment. Pharmaceutical compositions, such as topical and transdermal compositions, containing margaric acid and a pharmaceutically acceptable excipient are also described. A pain-relieving composition containing margaric acid, eicosapentaenoic acid, and a pharmaceutically acceptable excipient is further described.

Provided is a renal function maintenance and protection agent comprising as an active ingredient of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA), which can be used as a pharmaceutical or food composition.A triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) is used as an active ingredient for renal function maintenance and protection agents.

The invention provides a method for producing polyunsaturated fatty acid, and belongs to the technical field of biological fermentation. The method for producing polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid from schizochytrium limacinum comprises the following steps: activating schizochytrium limacinum in a seed culture medium to obtain a schizochytrium limacinum seed culture solution; inoculating the schizochytrium limacinum seed culture solution into a fermentation culture medium for culturing, wherein the fermentation culture medium comprises rapeseed protein powder; and extracting the culture solution in the cultured fermentation culture medium to obtain the polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid. According to the present invention, the yield of polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid can be significantly improved.

Botanical extracts are provided, which comprise ethanol extracts of Nannochloropsis algae having between 10wt% and 50wt% polar lipids and between 45wt% and 60wt% fatty acids, wherein the fatty acids comprise more than 10wt% of eicosapentaenoic acid (EPA) as triglyceride conjugates and / or diglyceride conjugates, and less than 15wt% EPA as free fatty acids. EPA level may reach up to 90wt%, and the botanical extract may be fluid at room temperature. Growth conditions are configured, adjusted and monitored to promote EPA formation in the cell vacuoles, resulting in a high proportion of EPA as tri / di-glyceride conjugates, as well as in a high concentration of Ω-3 fatty acids, which merely requires gentle extraction procedures to reach the final products, thereby maintaining the biochemical of the compounds without excessive modifications.

The application belongs to the technical field of biology, and discloses a Yarrowia lipolytica engineering strain for efficiently producing eicosapentaenoic acid based on citric acid metabolism regulation, a method and application, wherein a chassis strain of the engineering strain is Yarrowia lipolytica Po1f, and genes of Δ9 elongase, Δ8 desaturase, Δ5 desaturase and Δ17 desaturase in a fatty acid synthesis pathway, a heterologous ATP-citrate lyase and a mitochondrial citrate carrier are overexpressed. ATP-citrate lyases and mitochondrial citrate carrier genes respectively derived from Schizochytrium sp. and Saccharomyces cerevisiae are combined to be expressed in the Yarrowia lipolytica engineering strain, so that the production of EPA and oil in the Yarrowia lipolytica engineering strain is significantly improved, and compared with a control strain, the production of oil and EPA is respectively increased by 243.35% and 161.85%.

The invention provides a feed additive for increasing the content of n-3 polyunsaturated fatty acids in pork and a compound feed. The feed additive consists of spartina alterniflora powder and a bacterial enzyme additive, the bacterial enzyme additive is prepared from lactobacillus plantarum, aspergillus niger, yarrowia lipolytica, bacillus subtilis, cellulase, beta-mannase and protease; the compound feed comprises a basic ration and the feed additive. Through development and utilization of spartina alterniflora powder and practice, waste is turned into wealth, a new source of the feed additive is expanded, and the feed additive is added into daily ration, so that the digestibility of neutral detergent fibers of the daily ration is improved, the antioxidant capacity of serum is enhanced, and the contents of alpha-linolenic acid, arachidonic acid and eicosapentaenoic acid in pork are increased.

To provide extracted plant lipid or microbial lipid comprising docosapentaenoic acid (DPA), and processes for producing the extracted lipid.SOLUTION: Provided is extracted plant lipid or microbial lipid, comprising fatty acids in an esterified form, the fatty acids comprising oleic acid, palmitic acid, ω6 fatty acids which comprise linoleic acid (LA), ω3 fatty acids which comprise α-linolenic acid (ALA) and docosapentaenoic acid (DPA), and optionally one or more of stearidonic acid (SDA), eicosapentaenoic acid (EPA), and eicosatetraenoic acid (ETA), wherein the level of DPA in the total fatty acid content of the extracted lipid is between 7% and 35%.SELECTED DRAWING: None

The present invention relates to an orally administrable nutraceutical composition comprising omega- 3 fatty acids, at least one plant-derived extract exhibiting hypolipidemic activity, and an antioxidant. Hie composition is formulated as a nanoemulsion to enhance bioavailability, improve gastrointestinal absorption, and increase the therapeutic efficacy of the active compounds. The synergi stic interaction between omega- 3 fatty-7 acids and the bioactive component of plant extract promotes significant reduction in blood plasma triglyceride levels, supporting cardiovascular health. Hie formulation demonstrates improved pharmacokinetic parameters, including enhanced systemic exposure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), compared to commercially available omega- 3 supplements, including increased bioavailability under both fasted and fed conditions. This invention offers a novel strategy for enhancing the therapeutic efficacy of omega- 3 fatty acids in the management of cardiovascular diseases.

Described herein are retinoid compositions comprising (a) a retinoid preferably a C20-deuterated vitamin A that inhibits dimerisation to N-retinylidene-N-retinylethanolamine (A2E), (b) a lipid excipient preferably an omega-3 fatty acid comprising eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), and (c) a surfactant, wherein the compositions increase the bioavailability of the retinoid in a subject, and methods of using such retinoid compositions for treating eye conditions including macular degeneration.

The invention relates to the technical field of prevention and control of aquatic diseases, in particular to a preparation method of a pelteobagrus fulvidraco intestinal inflammation composite regulation preparation containing omega-3 fatty acid-lipoxin-phospholipid. The composite regulation and control preparation is prepared from the following functional components: 20 to 30 parts of eicosapentaenoic acid, 0.1 to 0.5 part of lipoxin B4, 8 to 12 parts of phosphatidylserine, 1 to 2 parts of dehydroabietic acid, 10 to 18 parts of sophorobiose and 0.01 to 0.03 part of ethoxyquin. The product integrates the functions of resisting bacteria, promoting inflammation regression and promoting tissue repair through a multi-target synergistic mechanism to construct a complete inflammation regulation and control pathway; meanwhile, by virtue of a nano-liposome dosage form technology, the active ingredients are effectively protected; the product is completely compounded from natural components to realize an antibacterial effect. According to the technical scheme, the technical problems of low antibacterial efficiency, single action mechanism, insufficient mucous membrane repair capability and the like of the existing prevention and control technology for the intestinal inflammation of the pelteobagrus fulvidraco can be solved, and the pelteobagrus fulvidraco has an ideal application prospect.

The invention provides a recombinant yarrowia lipolytica strain with high yield of eicosapentaenoic acid as well as a construction method and application of the recombinant yarrowia lipolytica strain, and belongs to the technical field of genetic engineering. The invention provides a recombinant yarrowia lipolytica strain Po1f: Y1 capable of reconstructing an EPA (eicosapentaenoic acid) synthetic route, and the recombinant yarrowia lipolytica strain Po1f: Y2 is constructed by taking the recombinant yarrowia lipolytica strain Po1f: Y1 as a host and overexpressing an LPCAT (Low Performance Protein Amino Transferase) mutant; and knocking out encoding genes such as PEX10, GUT2, TGL4, SNF1 and the like, and combining with overexpressed DGAT1 and the like to obtain a recombinant yarrowia lipolytica strain Po1f: Y3 with high yield of EPA. The recombinant yarrowia lipolytica strain Po1f: Y3 strain EPA accounts for 50% of the relative content of total fatty acid, the oil content accounts for 48% of the weight of stem cells, and the biomass of recombinant yeast in a 7.5 L fermentation tank exceeds 100 g stem cell weight / L.

Disclosed herein are pet food compositions for treating or preventing-inter alia-struvite urolithiasis comprising at least one of caprylic acid and capric acid; and at least one of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).

The object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism. The present invention relates to the following microorganisms, etc.: It is a microorganism capable of producing docosahexaenoic acid (DHA), which comprises a protein (mutant OrfB) composed of an amino acid sequence in which at least one of the amino acid residues at positions 6, 65, 230, 231 and 275 in the amino acid sequence represented by SEQ ID NO: 2 is replaced by other amino acid residues, and can produce eicosapentaenoic acid.

The invention discloses a sustainable asphalt regenerant, a preparation method and application, the sustainable asphalt regenerant comprises methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, methyl eicosenoate, methyl arachidonate and the like, the content of saturated fatty acid methyl ester exceeds 21.3-25.6% of the total content of fatty acid methyl ester, and the content of saturated fatty acid methyl ester exceeds 21.3-25.6% of the total content of fatty acid methyl ester. The content of unsaturated fatty acid methyl ester exceeds 66.2-70.5% of the total content of fatty acid methyl ester, and the total fraction is 100%; the regenerant is prepared from waste edible oil and fat as a raw material, and compared with a traditional petroleum-based regenerant, the regenerant is wide in source, low in raw material cost and renewable. The sustainable asphalt regenerant can effectively recover various properties of aged asphalt, and solves the problems of poor water damage resistance and durability caused by high content of acidic compounds in the existing waste edible oil asphalt regenerant; meanwhile, the recovery and reutilization of the waste edible grease and the aged asphalt material are realized.

The invention relates to the technical field of feed products, in particular to a composition and application thereof in preparation of a product for relieving diarrhea. The composition of the present invention comprises butyric acid, lauric acid, arachidonic acid, docosahexaenoic acid and eicosapentaenoic acid, or a precursor substance capable of releasing the aforementioned fatty acids in the digestive tract. The composition provided by the invention can effectively relieve diarrhea and inflammation, regulate intestinal flora and improve intestinal barrier integrity and intestinal health, and is used for preventing, relieving or treating intestinal diseases; the composition has an obvious relieving effect on diarrhea and enteritis of animals, compared with drugs such as antibiotics, the composition has higher safety and is not prone to drug resistance, and the composition can be used for treating intestinal diseases and can also be added into daily ration to improve intestinal health.

The present invention provides for a water-soluble composition comprising at least one source of Omega-3 comprising at least one Omega-3 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and alpha-linolenic acid (ALA), and micelle-promoting agents comprising one or more of carrier oils, solvents, emulsiiiers and antioxidants, in order to promote an increase in biovailability of the Omega-3 Source of at least two times.

A composition containing 96-99% by area of an eicosapentaenoic acid alkyl ester, the content of an arachidonic acid alkyl ester being 0.7% by area or less, and the content of a mono-trans body of the eicosapentaenoic acid alkyl ester being 2.5% by area or less. A method for producing a composition containing an eicosapentaenoic acid alkyl ester at a high concentration, the method comprising: subjecting a composition containing an eicosapentaenoic acid alkyl ester obtained by alkyl esterification of a raw oil containing eicosapentaenoic acid to precision distillation at a vacuum degree of 0.2 Torr or less and a temperature of 190 DEG C or less in the entire column; and performing concentration treatment on the composition after precision distillation by using chromatography.

The present invention relates to the technical field of microbial preparation, specifically to Schizochytrium sp. and its applications, as well as methods and products for producing EPA, DHA, and heptadecanoic acid. Schizochytrium sp. SK-3 was deposited at the China Center for Type Culture Collection on October 23, 2024, with the deposit number CCTCC NO: M 20242315. The application of Schizochytrium sp. SK-3 in the production of EPA, DHA, and high-yield heptadecanoic acid. This strain is cultured in a fermentation medium containing a carbon source, a nitrogen source, and inorganic salts at 20-30 °C for 72-96 hours to obtain oils containing long-chain fatty acids such as docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and heptadecanoic acid, which can be used to prepare food products, cosmetics, or pharmaceutical compositions for animals or humans.